AI-generated summary
The authors conducted a narrative review by a panel of specialists on photobiomodulation for oral adverse events of cancer treatment, covering oral mucositis, xerostomia, dysgeusia, dysphagia and trismus/fibrosis. They report promising outcomes in several nonroutine uses but note that the primary studies are often small and may have biases, particularly regarding safety. The authors state that robust evidence from large multicentered studies is needed before widespread clinical use.
- Who or what was studied
- Patients with oral adverse events of cancer treatment
- Limits stated in the abstract
- The primary studies are often small and may have biases, particularly regarding treatment safety, and the review is narrative rather than systematic.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Oral mucositis. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.